332 related articles for article (PubMed ID: 36704037)
1. The interplay between prolactin and cardiovascular disease.
Glezer A; Santana MR; Bronstein MD; Donato J; Jallad RS
Front Endocrinol (Lausanne); 2022; 13():1018090. PubMed ID: 36704037
[TBL] [Abstract][Full Text] [Related]
2. Increased carotid intima media thickness is associated with prolactin levels in subjects with untreated prolactinoma: a pilot study.
Jiang XB; Li CL; He DS; Mao ZG; Liu DH; Fan X; Hu B; Zhu YH; Wang HJ
Pituitary; 2014 Jun; 17(3):232-9. PubMed ID: 23756783
[TBL] [Abstract][Full Text] [Related]
3. Ropinirole for the Treatment of Hyperprolactinemia: A Dose-Escalation Study of Efficacy and Tolerability.
Heneghan LJ; Tsang A; Dimino C; Khandji AG; Panigrahi SK; Page-Wilson G
J Clin Endocrinol Metab; 2024 Jan; 109(2):e667-e674. PubMed ID: 37715962
[TBL] [Abstract][Full Text] [Related]
4. Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma.
Inancli SS; Usluogullari A; Ustu Y; Caner S; Tam AA; Ersoy R; Cakir B
Endocrine; 2013 Aug; 44(1):193-9. PubMed ID: 23233277
[TBL] [Abstract][Full Text] [Related]
5. Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study.
Posawetz AS; Trummer C; Pandis M; Aberer F; Pieber TR; Obermayer-Pietsch B; Pilz S; Theiler-Schwetz V
BMC Endocr Disord; 2021 Apr; 21(1):81. PubMed ID: 33902531
[TBL] [Abstract][Full Text] [Related]
6. Hemoglobin decline as a signal for hyperprolactinemia onset prior to prolactinoma diagnosis in hypogonadal men.
Rudman Y; Duskin-Bitan H; Richter I; Tsvetov G; Masri-Iraqi H; Akirov A; Shimon I
Andrology; 2023 Oct; 11(7):1398-1407. PubMed ID: 36897756
[TBL] [Abstract][Full Text] [Related]
7. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy.
Berinder K; Nyström T; Höybye C; Hall K; Hulting AL
Pituitary; 2011 Sep; 14(3):199-207. PubMed ID: 21128120
[TBL] [Abstract][Full Text] [Related]
8. Metabolic effects of prolactin and the role of dopamine agonists: A review.
Kirsch P; Kunadia J; Shah S; Agrawal N
Front Endocrinol (Lausanne); 2022; 13():1002320. PubMed ID: 36246929
[TBL] [Abstract][Full Text] [Related]
9. High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?
Espinosa-Cárdenas E; Sánchez-García M; Ramírez-Rentería C; Mendoza-Zubieta V; Sosa-Eroza E; Mercado M
Endocrine; 2020 Oct; 70(1):143-149. PubMed ID: 32548734
[TBL] [Abstract][Full Text] [Related]
10. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists.
dos Santos Silva CM; Barbosa FR; Lima GA; Warszawski L; Fontes R; Domingues RC; Gadelha MR
Obesity (Silver Spring); 2011 Apr; 19(4):800-5. PubMed ID: 20559294
[TBL] [Abstract][Full Text] [Related]
11. Prolactin in men's health and disease.
Bolyakov A; Paduch DA
Curr Opin Urol; 2011 Nov; 21(6):527-34. PubMed ID: 21941183
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for accelerated atherosclerosis in young women with hyperprolactinemia.
Medic-Stojanoska M; Icin T; Pletikosic I; Bajkin I; Novakovic-Paro J; Stokic E; Spasic DT; Kovacev-Zavisic B; Abenavoli L
Med Hypotheses; 2015 Apr; 84(4):321-6. PubMed ID: 25649851
[TBL] [Abstract][Full Text] [Related]
13. Concomitant Cushing's Disease and Marked Hyperprolactinemia: Response to a Dopamine Receptor Agonist.
Shiraishi J; Koyama H; Shirakawa M; Ishikura R; Okazaki H; Kurajoh M; Shoji T; Moriwaki Y; Yamamoto T; Namba M
Intern Med; 2016; 55(8):935-41. PubMed ID: 27086808
[TBL] [Abstract][Full Text] [Related]
14. Hypogonadism due to hyperprolactinemia and subsequent first episode of psychosis.
Tsigkaropoulou E; Peppa M; Zompola C; Rizos E; Xelioti I; Chatziioannou S; Filippopoulou A; Lykouras L
Gend Med; 2012 Feb; 9(1):56-60. PubMed ID: 22333523
[TBL] [Abstract][Full Text] [Related]
15. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
[TBL] [Abstract][Full Text] [Related]
16. Hyperprolactinemia and prolactinoma.
Romijn JA
Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of atherosclerosis after cessation of cabergoline therapy in patients with prolactinoma.
Doğan BA; Arduç A; Tuna MM; Nasıroğlu NI; Işık S; Berker D; Güler S
Anatol J Cardiol; 2016 Jun; 16(6):440-7. PubMed ID: 26680550
[TBL] [Abstract][Full Text] [Related]
18. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
19. Metabolic Syndrome in Hyperprolactinemia.
Andersen M; Glintborg D
Front Horm Res; 2018; 49():29-47. PubMed ID: 29894997
[TBL] [Abstract][Full Text] [Related]
20. Is there an increased cardiovascular risk in patients with prolactinoma? A challenging question.
Yazici D; Sunbul M; Yasar M; Deyneli O; Yavuz D
J Clin Ultrasound; 2021 Oct; 49(8):870-877. PubMed ID: 34131923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]